Suppr超能文献

一种KRAS反应性长链非编码RNA控制微小RNA加工。

A KRAS-responsive long non-coding RNA controls microRNA processing.

作者信息

Shi Lei, Magee Peter, Fassan Matteo, Sahoo Sudhakar, Leong Hui Sun, Lee Dave, Sellers Robert, Brullé-Soumaré Laura, Cairo Stefano, Monteverde Tiziana, Volinia Stefano, Smith Duncan D, Di Leva Gianpiero, Galuppini Francesca, Paliouras Athanasios R, Zeng Kang, O'Keefe Raymond, Garofalo Michela

机构信息

Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.

Cancer Research UK Lung Cancer Centre of Excellence, at Manchester and University College London, London, UK.

出版信息

Nat Commun. 2021 Apr 1;12(1):2038. doi: 10.1038/s41467-021-22337-3.

Abstract

Wild-type KRAS (KRAS) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role of KRAS overexpression in lung cancer progression is largely unexplored. Here, we identify and characterize a KRAS-responsive lncRNA, KIMAT1 (ENSG00000228709) and show that it correlates with KRAS levels both in cell lines and in lung cancer specimens. Mechanistically, KIMAT1 is a MYC target and drives lung tumorigenesis by promoting the processing of oncogenic microRNAs (miRNAs) through DHX9 and NPM1 stabilization while halting the biogenesis of miRNAs with tumor suppressor function via MYC-dependent silencing of p21, a component of the Microprocessor Complex. KIMAT1 knockdown suppresses not only KRAS expression but also KRAS downstream signaling, thereby arresting lung cancer growth in vitro and in vivo. Taken together, this study uncovers a role for KIMAT1 in maintaining a positive feedback loop that sustains KRAS signaling during lung cancer progression and provides a proof of principle that interfering with KIMAT1 could be a strategy to hamper KRAS-induced tumorigenesis.

摘要

野生型KRAS(KRAS)扩增已被证明是癌症中KRAS激活的一种次要方式,且与较差的生存率相关。然而,KRAS过表达在肺癌进展中的精确作用在很大程度上尚未得到探索。在此,我们鉴定并表征了一种KRAS反应性lncRNA,即KIMAT1(ENSG00000228709),并表明它在细胞系和肺癌标本中均与KRAS水平相关。从机制上讲,KIMAT1是MYC的一个靶点,通过DHX9和NPM1的稳定促进致癌性微小RNA(miRNA)的加工,同时通过MYC依赖的微小RNA加工复合体成分p21的沉默来阻止具有肿瘤抑制功能的miRNA的生物合成,从而驱动肺肿瘤发生。敲低KIMAT1不仅抑制KRAS表达,还抑制KRAS下游信号传导,从而在体外和体内抑制肺癌生长。综上所述,本研究揭示了KIMAT1在维持肺癌进展过程中维持KRAS信号传导的正反馈回路中的作用,并提供了一个原理证明,即干扰KIMAT1可能是一种阻碍KRAS诱导肿瘤发生的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79f4/8016872/2c76beba4ba7/41467_2021_22337_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验